Improving vaccines for tuberculosis
Official title: ADVANCING VACCINE ADJUVANT RESEARCH FOR TUBERCULOSIS (AVAR-T)
Funded at University of Sydney · NIH-11167404 · Data updated 2026-11-12
This study is looking to create better vaccines for tuberculosis, especially for people at higher risk like those with HIV, by testing different ingredients that help boost the vaccine's effectiveness in animals to find the best options for future vaccines.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Sydney NIH-funded |
| Lab location | 1 site (Sydney, Australia) |
| Project start | September 30, 2022 |
| Project end | September 29, 2027 |
| Funding year | 2024 |
| Award (this year) | $2,091,723 |
| NIH project number | 75N93022C00041-P00004-9999-1 |
| Project ID | NIH-11167404 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at high risk for tuberculosis, including those living with HIV.
✕Less likely to help
Patients who are not at risk for tuberculosis or those who have already been vaccinated may not benefit from this research.
What this research studies
This research focuses on developing better vaccines for tuberculosis (TB), particularly for individuals at higher risk, such as those living with HIV. The team will compare different vaccine adjuvants, which are substances that enhance the body's immune response to the vaccine, alongside specific TB antigens. By using mouse models and non-human primates, they aim to identify the most effective combinations that could lead to new TB vaccines. The ultimate goal is to create vaccines that can prevent TB infection and improve treatment outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines that significantly reduce the incidence of tuberculosis, especially in vulnerable populations.
How similar studies have gone: Previous research has shown promise in developing effective vaccine adjuvants for other diseases, suggesting potential success for this approach in tuberculosis.
Where this research is happening
-
University of Sydney
Sydney, Australia Active
Researchers
- Principal investigator: Britton, Warwick — University of Sydney
- Study coordinator: Britton, Warwick
Related research
Other NIH-funded projects on the same topics.
-
Coronary disease and immune activation in people with HIV and tuberculosis coinfection
This research looks at how having HIV and latent tuberculosis together might raise the risk of heart disease, and what immune changes are involved.
-
Pulmonary rehabilitation to reduce breathing problems after tuberculosis
A program of guided exercise and breathing training to help adults who have recovered from TB breathe better and feel healthier.
-
Pulmonary rehab to reduce breathing troubles after TB
A program of pulmonary rehabilitation is being studied to help adults who have completed TB treatment avoid ongoing lung problems and improve daily breathing.
-
Air pollution and tuberculosis spread in Kampala, Uganda
This project looks at whether dirty air from PM2.5 particles makes tuberculosis more likely to spread within urban slum households in Kampala, Uganda.
-
Air pollution and TB spread in Ugandan urban slums
This project explores whether exposure to air pollution makes tuberculosis more likely to spread within households in a crowded Ugandan slum.
-
Air pollution and TB transmission in Kampala’s urban slums
This project looks at whether air pollution from PM2.5 makes tuberculosis spread more easily from infected people to their neighbors in urban slums of Kampala, Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.